Gabapentin can significantly improve dystonia severity and quality of life in children

Area of Science:

• Pediatric Neurology
• Movement Disorders
• Pharmacology

Background:

• Gabapentin is utilized for neuropathic pain, epilepsy, and movement disorders.
• Severe dystonia in children presents significant challenges in motor function and daily activities.

Purpose of the Study:

• To evaluate the efficacy of gabapentin in managing severe pediatric dystonia.
• To assess the impact of gabapentin on motor severity, daily living activities, and quality of life in children with dystonia.

Main Methods:

• A retrospective observational study analyzed data from 69 children with severe dystonia.
• Motor severity was assessed using the Gross Motor Function Classification System (GMFCS) and Dystonia Severity Assessment Plan (DSAP).
• Improvements in daily activities were graded using the WHO International Classification of Functioning, Disability and Health, Children & Youth version (ICF-CY).

Main Results:

• The majority of participants (69 children) were classified as GMFCS level 5 (non-ambulant).
• Gabapentin significantly reduced dystonia severity (DSAP grade from 3 to 1).
• Significant improvements were observed in sleep quality, sleep duration, mood, pain, muscle tone, involuntary movements, and seating tolerance (p < 0.01).
• Higher mean doses of gabapentin were required for dystonia compared to pain relief without dystonia (18.1 mg/kg/dose vs 7.61 mg/kg/dose).

Conclusions:

• Gabapentin demonstrates significant potential in ameliorating dystonia severity in children.
• Treatment with gabapentin can lead to improved activities of daily living and enhanced quality of life for pediatric patients with severe dystonia.